IL6 and neoplasm: Regarding the downregulation of IL-6 mediated by SOCS3 overexpression, as early as two hours after exposure to 15d-PGJ2, and considering the detrimental effects and actions of IL-6 linked with tumor growth, progression, and relapse [55–57], 15d-PGJ2 is presented as a novel antineoplastic drug.